Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause: a clinical trial

Table 2 Clinical and anthropometric variables and menopausal symptoms (n = 86)

	Baseline	E2	E2+P	P
BMI	26.3 ± 3	26.29 ± 3	26.23 ± 3.1	0.8
Weight (kg)	65.5 ± 8.3	65.58 ± 8.3	65.4 ± 8.6	0.7
Waist circumference (cm)	84.3 ± 7.5	84.2 ± 7.6	83.5 ± 7.4	0.06
Systolic blood pressure	118.6 ± 13.5	115 ± 14.9	116.7 ± 14.3	0.1
Diastolic blood pressure	76.2 ± 7.3	74.7 ± 9.5	74.9 ± 9.7	0.4
Kupperman score	26 (17–30)^a	6 (0–12.5)^b	4 (0–8)^b	< 0.01
E2 (pg/mL)	13 (5–19)^a	54 (13–122)^b	48 (13–80)^b	< 0.01

Values expressed as median and interquartile range or mean ± SD. P = two-way analysis of variance with repeated measures (non parametric variables were log-converted for statistical analysis and reconverted for presentation in table format).
Different superscript letters indicate statistical difference with Bonferroni multiple-comparison correction test (α < 5%).
Baseline: before hormone therapy; E2: estradiol only; E2+P estradiol + micronized progesterone.
BMI body mass index.

ISSN: 1476-511X